31 completed, 8 active not recruiting, 6 recruiting, 6 terminated. 52 Phase 2, 6 Phase 1, 1 Phase 3.
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations. Zongertinib (BI 1810631), Fulvestrant - Advanced Breast Cancer, Hormone Receptor Positive / HER2-negative Breast Cancer | Phase 2 | Not yet recruiting | MedSIR | 25 | 2026-10-04 | 2026-06-01 |
| A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma. bexmarilimab, Doxorubicin - Soft Tissue Sarcoma (STS) | Phase 1 / Phase 2 | Recruiting | MedSIR | 278 | 2026-08-20 | 2026-08-31 |
| A COMPREHENSIVE BIOMARKER EVALUATION IN BILIARY TRACT CANCER No intervention - Biliary Tract Cancer (BTC) | Not yet recruiting | MedSIR | 244 | 2026-07-01 | 2026-04-07 | |
| Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer Zanidatamab, Tucatinib, Capecitabine - HER 2 Positive Advanced Breast Cancer, Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | MedSIR | 24 | 2026-07-01 | 2026-04-23 |
| Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer Sacituzumab Govitecan (SG), Atropine, G-CSF (Granulocyte colony-stimulating factor) - Breast Cancer, Advanced HR+/HER2- Breast Cancer | Phase 2 | Not yet recruiting | MedSIR | 30 | 2026-07-01 | 2026-01-28 |
| Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases Radiotracer targeting somatostatin receptor 2 (SSTR2) ([68Ga]Ga-DOTA-TOC) - Solid Tumors, HER2-positive Breast Cancer | Phase 2 | Not yet recruiting | MedSIR | 10 | 2026-04-30 | 2025-11-14 |
| Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC Zimberelimab (AB122), Domvanalimab (DOM), Sacituzumab Govitecan (SG) - Triple Negative Breast Cancer, PDL-1 Positive | Phase 2 | Withdrawn | MedSIR | 2026-04-01 | 2026-05-01 | |
| Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer Camizestrant, Ribociclib - Hormon Receptor Positive Breast Cancer, Breast Cancer | Phase 2 | Recruiting | MedSIR | 150 | 2026-03-24 | 2026-05-29 |
| Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype Trastuzumab deruxtecan (T-DXd, DS-8201a), CDK4/6i plus ET - Advanced Breast Cancer, Advanced Breast Carcinoma | Phase 2 | Recruiting | MedSIR | 200 | 2025-06-30 | 2026-07-30 |
| Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis Repotrectinib - NSCLC, Brain Metastases | Phase 2 | Recruiting | MedSIR | 20 | 2025-06-27 | 2026-09-09 |
| Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain Metastases Datopotamab deruxtecan - Non-small Cell Lung Cancer | Phase 2 | Withdrawn | MedSIR | 2025-06-01 | 2025-08-08 | |
| Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer Pembrolizumab, Carboplatin, Paclitaxel - Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Completed | MedSIR | 31 | 2025-05-29 | 2026-07-27 |
| Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer Debio 0123 and Sacituzumab govitecan - Advanced Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | MedSIR | 76 | 2025-01-17 | 2025-12-05 |
| Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. Everolimus, Elacestrant, Placebo - Advanced Breast Cancer, ER-positive Breast Cancer | Phase 3 | Recruiting | MedSIR | 300 | 2024-12-05 | 2026-08-24 |
| Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression Niraparib oral tablets - Ovarian Cancer, Oligometastatic Disease | Phase 2 | Recruiting | MedSIR | 30 | 2024-12-03 | 2026-04-22 |
| PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer Trastuzumab deruxtecan, Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection, Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection - HER2-positive Breast Cancer | Phase 2 | Active not recruiting | MedSIR | 165 | 2024-07-22 | 2026-04-29 |
| T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases Trastuzumab-Deruxtecan (T-DXd) - Breast Cancer, Metastatic Breast Cancer | Phase 2 | Active not recruiting | MedSIR | 28 | 2024-06-05 | 2026-05-08 |
| A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population Giredestrant, Abemaciclib, Inavolisib - Breast Cancer | Phase 2 | Active not recruiting | MedSIR | 976 | 2024-04-01 | 2026-09-24 |
| HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease Patritumab deruxtecan - Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer | Phase 2 | Completed | MedSIR | 63 | 2023-11-24 | 2026-05-04 |
| Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy Nivolumab, Ipilimumab, Carboplatin - Carcinoma, Non-Small-Cell Lung | Phase 2 | Terminated | Hackensack Meridian Health | 5 | 2023-09-29 | 2026-09-23 |
Showing 20 of 60. Sign in to see all of them.
Breast Neoplasms (31) · Triple Negative Breast Neoplasms (6) · Neoplasm Metastasis (5) · Brain Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (4) · Prostatic Neoplasms (2) · Recurrence (2) · Biliary Tract Neoplasms (1) · COVID-19 (1) · Carcinoma, Endometrioid (1) · Endometrial Neoplasms (1) · Hyperglycemia (1) · Ketosis (1) · Lung Neoplasms (1) · Meningeal Carcinomatosis (1)
Letrozole (7) · eribulin (7) · Fulvestrant (6) · Paclitaxel (5) · palbociclib (5) · pembrolizumab (5) · Carboplatin (4) · Trastuzumab (4) · sacituzumab govitecan (4) · trastuzumab deruxtecan (4) · Capecitabine (3) · Tamoxifen (3) · atezolizumab (3) · ipatasertib (3) · olaparib (3)
Spain (48) · Italy (13) · France (11) · Germany (11) · United Kingdom (11) · Portugal (6) · Austria (5) · Czechia (3) · Belgium (2) · United States (2) · Brazil (1) · Bulgaria (1) · Greece (1) · Hungary (1) · Netherlands (1)
Antonio Llombart, MD (6) · Antonio Llombart (3) · Antonio Llombart-Cussac, MD (3) · Antonio Llombart-Cussac (2) · Javier Cortes (2) · Matthias Preusser, MD (2) · Peter Schmid (2) · Tim Robinson, BMBS, PhD (2) · Antonio Calles (1) · Antonio Llombart, MD, PhD (1) · Antonio Llombart, PdH (1)
PMID 33763756, PMID 33794440, PMID 34019819, PMID 34617955, PMID 34763195, PMID 35981452, PMID 36239405, PMID 36300423, PMID 38575192, PMID 38582092, PMID 38587643, PMID 39255534, PMID 39265579, PMID 39520738, PMID 39938593, PMID 40018758, PMID 40294349, PMID 40447851, PMID 40467896, PMID 40770648, PMID 40907517, PMID 41167214, PMID 41167215, PMID 42875559
2016 (6), 2023 (6), 2019 (5), 2018 (4), 2025 (4), 2015 (3), 2017 (3), 2014 (2)